Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. (Q36003480)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Tiziano Barbui

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Giovanni Barosi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Alessandro Rambaldi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Roberto Marchioli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Arianna Masciulli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Flavia Biamonte

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Elisabetta Gattoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Maria Letizia Lupo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Guido Finazzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Elisabetta Antonioli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Maria Chiara Susini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Elisa Malevolti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Emilio Usala

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Ubaldo Occhini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Alberto Grossi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Silvia Caglio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Simona Paratore

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Alessandro M Vannucchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

1 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

2069-2076

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

6 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

How I treat myelofibrosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Advances in understanding and management of myeloproliferative neoplasms

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Defining the role of mTOR in cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

From palliation to targeted therapy in myelofibrosis.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3365876

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

23 September 2018

1 reference

12 December 2020

Myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

10.1182/BLOOD-2011-01-330563

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

21725052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21725052%20AND%20SRC:MED&resulttype=core&format=json